Polymorphic N-acetylation of a caffeine metabolite

Area of Science:

• Pharmacogenetics
• Human Metabolism
• Biochemistry

Background:

• Caffeine metabolism exhibits significant inter-individual and inter-ethnic variability in human populations.
• A newly discovered caffeine metabolite, 5-acetylamino-6-formylamino-3-methyluracil (AFMU), shows bimodal distribution in urine.
• This variability suggests a genetic component influencing caffeine breakdown pathways.

Purpose of the Study:

• To investigate the potential role of the polymorphic N-acetyltransferase enzyme (NAT) in the formation of AFMU.
• To determine if the known acetylation polymorphism is responsible for the observed variability in AFMU levels.
• To establish a link between NAT phenotype and AFMU production in humans.

Main Methods:

• Urinary AFMU levels were measured in Caucasian and Oriental subjects from Toronto.
• A subset of 20 subjects underwent phenotyping for N-acetyltransferase (NAT) activity using sulfamethazine (SMZ).
• Correlation analysis was performed between AFMU production and SMZ acetylation status.

Main Results:

• Urinary AFMU levels demonstrated both bimodal distribution and inter-ethnic variability.
• A strong concordance was observed between AFMU production and sulfamethazine (SMZ) acetylation status across all tested subjects.
• This concordance indicates a direct relationship between the acetylation polymorphism and AFMU formation.

Conclusions:

• The N-acetyltransferase (NAT) polymorphism is strongly implicated in the metabolic pathway leading to AFMU production in humans.
• Understanding this genetic variation is crucial for interpreting caffeine metabolism studies and individual responses.
• This finding contributes to the field of pharmacogenetics, specifically concerning caffeine and its metabolites.